Estimate Recalculated Nov 4, 2024 02:33AM EST
Brian K Halak does not have any significant net worth to report based on the numbers we have. This is based on reported shares across multiple companies, which include Dicerna Pharmaceuticals Inc, Volcano Corp, Bionano Genomics, Inc., Orexigen Therapeutics, Inc., ZOGENIX, INC., TANDEM DIABETES CARE INC, MARINUS PHARMACEUTICALS INC, GLAUKOS Corp, VERACYTE, INC., Atara Biotherapeutics, Inc., Aldeyra Therapeutics, Inc., Vanda Pharmaceuticals Inc., Syndax Pharmaceuticals Inc, Esperion Therapeutics, Inc., Clovis Oncology, Inc., Alliqua BioMedical, Inc., OBALON THERAPEUTICS INC, Evoke Pharma Inc, aTYR PHARMA INC, ALIMERA SCIENCES INC, OTONOMY, INC., Neothetics, Inc., NOVACEA INC, Durata Therapeutics, Inc., Ocera Therapeutics, Inc., Achaogen Inc, Regado Biosciences Inc, ACHILLION PHARMACEUTICALS INC, Celator Pharmaceuticals Inc, CADENCE PHARMACEUTICALS INC, and Northstar Neuroscience, Inc..
Brian K Halak's CIK is 0001354718
2014 was Brian K Halak's most active year for acquiring shares with 4 total transactions. Brian K Halak's most active month to acquire stocks was the month of May. 2008 was Brian K Halak's most active year for disposing of shares, totalling 1 transactions. Brian K Halak's most active month to dispose stocks was the month of February. 2019 saw Brian K Halak paying a total of $0.00 for 50,000 shares, this is the most they've acquired in one year. In 2008 Brian K Halak cashed out on 4,297 shares for a total of $53,325.77, their largest year based on trade value.
Attention insiders:Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!